Metagenomi Therapeutics Shares Outstanding 2022-2025 | MGX
Metagenomi Therapeutics shares outstanding from 2022 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
|
Metagenomi Therapeutics Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2024 | 33 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 3 |
|
Metagenomi Therapeutics Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025-09-30 | 37 |
| 2025-06-30 | 37 |
| 2025-03-31 | 37 |
| 2024-12-31 | 33 |
| 2024-09-30 | 37 |
| 2024-06-30 | 37 |
| 2024-03-31 | 21 |
| 2023-12-31 | 3 |
| 2023-09-30 | 3 |
| 2023-06-30 | 3 |
| 2023-03-31 | 3 |
| 2022-12-31 | |
| 2021-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.055B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.071B | 12.09 |
| BridgeBio Pharma (BBIO) | United States | $14.501B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.806B | 18.36 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.915B | 23.87 |
| Bausch Health Cos (BHC) | Canada | $2.222B | 1.58 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.310B | 9.44 |
| Taysha Gene Therapies (TSHA) | United States | $1.246B | 0.00 |
| Personalis (PSNL) | United States | $0.729B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.422B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.187B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |